Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Coeptis Therapeutics Holdings, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/12/2023 |
8-K
| Quarterly results |
| 09/26/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 08/22/2023 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Other Events, Financial State...|
Docs:
|
"License Agreement, by and between Coeptis Therapeutics Holdings, Inc. and Deverra Therapeutics, Inc",
"Sublicense Agreement, by and between Coeptis Therapeutics Holdings, Inc. and Deverra Therapeutics, Inc",
"Asset Purchase Agreement, by and between Coeptis Therapeutics Holdings, Inc. and Deverra Therapeutics, Inc",
"Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics" |
|
| 08/11/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 06/16/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Underwriting Agreement by and between Coeptis Therapeutics Holdings, Inc. and Ladenburg Thalmann & Co. Inc",
"Warrant Agency Agreement, by and between Coeptis Therapeutics Holdings, Inc. and Continental Stock Transfer & Trust Company",
"Form of Pre-Funded Warrant",
"Form of Series A Warrant",
"Form of Series B Warrant",
"Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten Offering WEXFORD, Pa., June 14, 2023 -- Coeptis Therapeutics Holdings, Inc. , a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced the pricing of an underwritten offering for gross proceeds of approximately $3.5 million to a single healthcare focused investor prior to deducting underwriting discounts and commissions and offering expenses. The offering is comprised of 2,150,000 shares of common stock, 1,350,000 pre-funded warrants, 3,062,500 Series A Warrants with an exercise price of $1.65 per share and a term of five years following the initial exercise date, and 3,062,500 Series B Warrants with an exercise price of $1.65 per share and a term of five years fol...",
"Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering WEXFORD, Pa., June 16, 2023 -- Coeptis Therapeutics Holdings, Inc. , a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced the closing of an underwritten offering for gross proceeds of approximately $3.5 million to a single healthcare focused investor prior to deducting underwriting discounts and commissions and offering expenses. The offering was comprised of 2,150,000 shares of common stock, 1,350,000 pre-funded warrants, 3,062,500 Series A Warrants with an exercise price of $1.65 per share and a term of five years following the initial exercise date, and 3,062,500 Series B Warrants with an exercise price of $1.65 per share and a term of five years fo..." |
|
| 06/09/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ... |
| 06/06/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 05/31/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 05/17/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/06/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/31/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 12/29/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 11/18/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/07/2022 |
SC 13D
| Bull Horn Holdings Sponsor LLC reports a 21.7% stake in COEPTIS THERAPEUTICS HOLDINGS, INC. |
| 11/07/2022 |
SC 13G/A
| Lisa Pharma, LLC reports a 7.3% stake in 1 Coeptis Therapeutics Holdings, Inc. |
| 11/07/2022 |
SC 13G/A
| Lena Pharma, LLC reports a 7.3% stake in 1 Coeptis Therapeutics Holdings, Inc. |
| 11/03/2022 |
8-K
| Quarterly results |
| 10/28/2022 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 10/26/2022 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 10/26/2022 |
8-K
| Quarterly results |
| 10/11/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 10/03/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 09/30/2022 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 09/30/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 09/29/2022 |
S-4/A
| Form S-4/A - Registration of securities, business combinations: [Amend] |
| 09/26/2022 |
S-4/A
| Form S-4/A - Registration of securities, business combinations: [Amend] |
| 09/12/2022 |
S-4/A
| Form S-4/A - Registration of securities, business combinations: [Amend] |
| 08/22/2022 |
S-4/A
| Form S-4/A - Registration of securities, business combinations: [Amend] |
| 07/06/2022 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 07/06/2022 |
8-K
| Quarterly results |
| 07/05/2022 |
S-4/A
| Form S-4/A - Registration of securities, business combinations: [Amend] |
| 05/25/2022 |
S-4
| Form S-4 - Registration of securities, business combinations: |
| 05/20/2022 |
8-K
| Quarterly results |
| 05/10/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
|
|
|